Through this investment, Helios develops a strategic partnership that aims at synergistic effects of the development of cancer immunity cell therapy centered on Gaia BioMedicine’s know-how on NK cells, and Helios’ own specialized stem cell technology. In addition, Helios will purchase shares of Gaia Biochemical Corporation. Natural killer (NK) cells are a naturally occurring defense mechanism in the human body. The leukocyte attacks cancer cells and virus-infected cells, and in the classification of white blood cells is classified as a lymphocyts. The effectiveness of treatment with NK cells is expected to extend life expectancy, alleviate symptoms, improve quality of life, and cure.

Gaia BioMedicine news release, February 14, 2018